PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, Forum) announced on Wednesday that it has signed an agreement with
Asterion Cannabis Inc. for a worldwide licence to use, manufacture, distribute and sell three Health Canada-approved natural health products over the next five years. PreveCeutical will pay to Asterion a 20% royalty of the products' gross sales.
More information can be found
here.
PreveCeutical was in the news last week when
it announced the first product development program in its newly-created medicinal cannabis division that focuses on the development of cannabinoids as a preventive treatment for anxiety disorders.
FULL DISCLOSURE: PreveCeutical Medical Inc. is a paid client of Stockhouse Publishing.